India'S Dengue Vaccine Final Trials And K-P Action Plan Launch

As of February 27, 2026, India is on the verge of a significant breakthrough in the fight against dengue fever with the final Phase III trials of the DengiAll vaccine underway, developed by Panacea Biotec. This vaccine, which aims to be one of the world's first single-dose solutions for dengue, has been in development for nearly 15 years. The urgency of this trial is underscored by the World Health Organization's alarming statistics, indicating that nearly half the global population is at risk of dengue, with 100-400 million infections annually. In India alone, over one million cases and at least 1,500 deaths have been reported since 2021. "We will try to get this vaccine out there as soon as possible," stated Syed Khalid Ali, chief scientific officer of Panacea. If successful, DengiAll could be rolled out as early as next year, making it the first dengue vaccine available in India, where no licensed vaccine currently exists for public use.